Health Care Equipment & Supplies · NYSE

EWEdwards Lifesciences Corp

Last close
$107.15 +1.3%
52-week range
$74.66 to $107.69
Market cap
$61.6B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$6.07B
+12% vs FY24
Net income
$1.07B
-74% vs FY24
Free cash flow
$1.33B
+360% vs FY24
Net cash
$3.63B
Cash $4.23B, debt $598M

Stock price

+256% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on 2 of 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
60.6x
9.5x70.2x
92nd percentile, above its median of 42.2x
Price / sales
9.2x
6.5x15.6x
45th percentile, below its median of 9.8x
EV / EBITDA
35.7x
20.5x57.4x
62nd percentile, above its median of 30.8x
Price / free cash flow
43.3x
29.1x213x
28th percentile, below its median of 51.2x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
60.6x
Earnings yield
1.6%
Price / sales
9.2x
Price / book
5.7x
Price / operating cash flow
35.9x
EV / EBITDA
35.7x
EV / sales
8.6x
Free cash flow yield
2.3%

Profitability

Gross margin
78.0%
Operating margin
21.6%
Net margin
15.3%
Return on equity
9.4%
Return on capital
8.7%

Growth per year

Revenue, 3 years
+10.8%
Revenue, 5 years
+6.7%
Revenue, 9 years
+8.3%
EPS, 3 years
-9.1%

Balance sheet

Cash and investments
$4.64B
Total debt
$599M
Net cash
$4.05B
Debt / equity
0.06x
Current ratio
4.60x

Shares and dividend

Shares outstanding
575M
Share count, 5 years
-7.3%
Beta, 1 year
0.54
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $1.72B
RevenueNet income
Gross profitLatest quarter $1.35B
EBITDALatest quarter $344M
Margins78 / 17 / 18%
GrossOperatingNet
Earnings per shareLatest quarter $0.53
Cash flowLatest quarter $570M
OperatingCapexFree
Cash vs debtLatest quarter $4.64B
Cash and investmentsTotal debt
P/E historyNow 60.6x
P/E, median 42.2x dashed
P/S historyNow 9.2x
P/S, median 9.8x dashed

Where the revenue comes from

Transcatheter Mitral and Tricuspid Therapies went from 3% to 9% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

Transcatheter Aortic Valve ReplacementSurgical Heart Valve TherapyTranscatheter Mitral and Tricuspid Therapies
FY22
79%19%
$4.46B
FY23
77%19%
$5.01B
FY24
75%18%
$5.44B
FY25
74%17%9%
$6.07B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Transcatheter Aortic Valve Replacement$4.49B74.0%+9%
Surgical Heart Valve Therapy$1.03B17.0%+5%
Transcatheter Mitral and Tricuspid Therapies$551M9.1%+56%

Health Care Equipment & Supplies peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ABT Abbott Laboratories $188B +10% 13.8%40.4x3.9x 60th percentile
DHR Danaher Corp $164B +6% 20.4%38.1x6.4x 65th percentile
ISRG Intuitive Surgical Inc $154B +20% 28.4%53.7x13.3x 48th percentile
MDT Medtronic plc $132B +10% 18.1%25.3x3.5x 20th percentile
SYK Stryker Corp $118B +8% 20.7%33.0x4.5x 30th percentile
EW Edwards Lifesciences Corp $61.6B +13% 21.6%60.6x9.2x 92nd percentile

The company

Sector
Health Care
Industry
Health Care Equipment & Supplies
Founded
1956
Headquarters
Irvine, CA
Fiscal year ends
December
Website
EdwardsLifesciences.com

What it does

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about EW.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 1,039 active funds. Crowd level: quiet.

Open the Smart money tab